ERBB2 and metastatic neoplasm: The lower number of lesions per patient reflects the real-world setting of patients actively receiving HER2-targeted therapy, in contrast to studies such as IMPACT-MBC, which enrolled patients with newly diagnosed metastatic disease, a population that typically has a higher disease burden.